Form 4: Amgen CFO Peter Griffith Receives Equity Grant

Amgen EVP and CFO Peter H. Griffith was granted 3,640 restricted stock units and 23,752 non-qualified stock options.

Summary

• Peter H. Griffith, EVP and CFO of Amgen Inc., received a grant of 3,640 Restricted Stock Units (RSUs) on May 5, 2026.
• The reporting person was also granted 23,752 non-qualified stock options with an exercise price of $329.59.
• On May 6, 2026, 502 shares were withheld by the company to cover tax obligations related to the vesting of equity, at a price of $329.59 per share.
• Following these transactions, the reporting person holds 50,706 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding executive compensation, which carries a neutral sentiment.

Positives

• The equity grant aligns the interests of the CFO with long-term shareholder value creation.
• The vesting schedule of four equal annual installments encourages long-term retention of key executive talent.

Negatives

• The transaction involves the withholding of shares for tax purposes, which is a standard administrative procedure but results in a slight reduction of direct holdings.

Risks

• The value of the granted options is subject to market volatility and the future performance of Amgen's common stock price relative to the $329.59 exercise price.

Future Outlook

The equity grants are subject to a four-year vesting schedule, indicating management's commitment to the company's long-term strategic objectives through 2030.

Management Comments

• No specific narrative comments were provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that executive equity grants are standard practice in the biopharmaceutical industry to ensure leadership retention and alignment with long-term R&D and commercialization milestones.

Comparison to Industry Standards

• The use of a four-year vesting schedule is consistent with standard corporate governance practices for large-cap pharmaceutical companies like Pfizer, Gilead, and AbbVie.
• The grant of both RSUs and stock options is a common compensation structure for C-suite executives in the S&P 500.

Stakeholder Impact

• Shareholders may view the long-term vesting schedule as a positive signal for management stability.

Next Steps

• Vesting of the first 25% installment of RSUs and options on May 5, 2027.

Key Dates

Keywords

Amgen, AMGN, CFO, Equity Incentive Plan, Insider Trading, Form 4, Stock Options, Restricted Stock Units